Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf,David Siegel,Hartmut Goldschmidt,Katharine Hazell,Priscille Bourquelot,Bourras R. Bengoudifa,Jeffrey Matous,Ravi Vij,Margarida Magalhaes-Silverman,Rafat Abonour,Kenneth C. Anderson,Sagar Lonial

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

2012

Jeffrey L. Wolf
David Siegel
Hartmut Goldschmidt
Katharine Hazell
Priscille Bourquelot
Bourras R. Bengoudifa
Jeffrey Matous
Ravi Vij
Margarida Magalhaes-Silverman
Rafat Abonour
Kenneth C. Anderson
Sagar Lonial

Novel therapies such as bortezomib and immunomodulatory agents (IMiDs®) have significantly improved the survival of patients with multiple myeloma (MM) [1]. However, the prognosis remains poor for ...

Keywords:

Diabetes mellitus
Oncology
Panobinostat
Refractory Multiple Myeloma
Immunology
Internal medicine
Medicine
single agent
Multiple myeloma
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

104

Citations